France· FR:66266368
RIZMOIC 200 microgrammes, comprimé pelliculé
A naldemedine product containing tosylate de naldémédine, registered in France by SHIONOGI (PAYS BAS), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Naldemedine is registered in 14 of 19 countries.
Countries holding a registration under ATC A06AH05 (naldemedine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Naldemedine · ATC A06AH05
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of naldemedine costs, country by country.
Normalised to the WHO defined daily dose (0.2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Naldemedine · price per daily dose (0.2 mg)
USD · FX 28 Sept 2026
- IT Italy$2.82
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TOSYLATE DE NALDÉMÉDINE
- Manufacturer
- SHIONOGI (PAYS BAS)
- Country
- France (FR)
- ATC code
- A06AH05
- ATC class
- Naldemedine
- Defined daily dose
- 0.2 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400930278406plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)EUR 50.26
- cip13340093032317530 plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 1 comprimé(s)EUR 50.26
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
174 interactions on record for naldemedine.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Naldemedine · interactions on record
174 records
- 12 severe
- 160 moderate
- 2 minor
Most severe, free to view
- RifampicinJ04AB02severe
- RifapentineJ04AB05severe
- MitotaneL01XX23severe
- EnzalutamideL02BB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Naldemedine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRIZMOICShionogi B.V., Amsterdam
- SpainRIZMOIC 200 MICROGRAMOS COMPRIMIDOS RECUBIERTOS CON PELICULAShionogi B.V.
- FinlandRizmoicShionogi B.V.
- United KingdomRizmoic 200microgram tabletsViatris UK Healthcare Ltd
- IrelandRizmoic 200 microgram Film-coated tabletShionogi B.V.
- IcelandRizmoicShionogi B.V.
- ItalyRIZMOIC*28 cpr rivestite 200 mcgSHIONOGI B.V.
- NetherlandsRizmoic 200 microgram, filmomhulde tabletShionogi Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rizmoic
- Liechtenstein · Rizmoic
- Norway · Rizmoic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c60b899c-b5ac-4a2d-b8c0-b6edf5d27dba GET /v1/drugs/c60b899c-b5ac-4a2d-b8c0-b6edf5d27dba?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66266368",
"date_amm": "2019-02-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1291",
"substance": "TOSYLATE DE NALDÉMÉDINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about naldemedine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.